Therapeutic antibodies are a rapidly growing class of drugs. Their application areas are not only limited to the standard immunoglobulin G (IgG) format but can also be extended to novel formats, including antibody fragments (scFv, VHH), drug conjugates and bispecifics. This webinar explores platform selection and development strategies for generating high-performance anti-idiotype (anti-ID) antibodies to support pharmacokinetic (PK) and anti-drug antibody (ADA) assays. To ensure their safety and efficacy, regulatory agencies and pharmaceutical developers rely on two essential types of assays: PK assays and ADA assays. PK measures how a drug is absorbed, distributed, metabolized and eliminated in the body. ADA assays are designed to detect and measure the immunogenicity of an antibody drug after treatment. Anti-ID antibodies bind to the idiotype, a specific epitope group on the variable region, of another antibody, usually an antibody drug. High-performance anti-IDs are critical for developing sensitive, specific and robust PK and ADA assays to support pre-clinical and clinical studies in drug development programs. High sensitivity and specificity, strong affinity and well-defined epitope-binding specificity are important features for anti-IDs. Rabbit monoclonal antibodies (mAbs) are known for their high affinity and diversity, making them a valuable source of highly specialized research reagents. The lower homology of the antibody drug to rabbit germline sequences compared with mice suggests that rabbits may generally mount a stronger immune response to an antibody drug than mice. An optimized rabbit B cell cloning platform can support the discovery of high-quality anti-IDs with high sequence diversity and affinity, including blocker